Express Mail Number: EK611[redacted]623US
Date of Deposit: March 23, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Mehta *et al.*		
ASSIGNEES:	CuraGen Corporation		
SERIAL NUMBER:	09/351,617	EXAMINER:	P. Ponnaluri
FILING DATE:	July 12, 1999	ART UNIT:	1627
FOR:	GENERAL SCREENING METHOD FOR LIGAND-PROTEIN INTERACTIONS		

Assistant Commissioner for Patents
Washington, D.C. 20231

12/Brp 4601

REPLY UNDER 37 C.F.R. 1.111
TO OFFICE ACTION DATED OCTOBER 23, 2000

This is in response to the Office Action mailed October 23, 2000 ("Office Action"). In the Office Action, the Examiner rejected all pending claims, namely claims 1, 6, 12-24, 26, 27 and 31. Prior to examination, please consider the following amendments and remarks.

AMENDMENTS

In the Combined Declaration and Power of Attorney

Please accept the Supplemental Combined Declaration and Power of Attorney, executed by Vimal D. Mehta on March 12, 2001, with his correct post office and residence address.

In the Specification

Please replace the paragraph at page 10, lines 13 to 23, with the following:

--Modified aspirin (aminoalkyl salicylates) were synthesized as shown in FIG. 3. The Dexamethasone (Sigma Chemical Co., St. Louis, MO) and FK506 (Fujisawa Pharmaceuticals) were linked to aminoalkyl salicylates to form a hybrid molecule. The chemistry utilized to effect the linkage is shown in FIG. 3. The dexamethasone and FK506 hybrid molecule with aminosalicylates were synthesized utilizing synthetic transformations outlined in FIG. 3. The dexamethasone portion of the hybrid molecule was synthesized as dexamethasone free amine starting from commercially available dexamethasone in three synthetic modifications (Licura, et.